Abstract
Background: This study identified factors associated with recent cannabis use and cannabis use for medical purposes among cancer survivors relative to individuals without a history of cancer.
Methods: Data from the Behavioral Risk Factor Surveillance System were analyzed for the 22 states completing the optional cannabis module in 2020. Weighted multiple logistic regression was performed to explore variables associated with past 30-day cannabis use and cannabis use for medical purposes, stratified by history of cancer. Covariates included state-level cannabis policy, sociodemographic characteristics, health status indicators, and substance use.
Results: Cannabis use was lower among cancer survivors compared to individuals with no history of cancer (7.57% vs. 10.83%). However, a higher proportion of cancer survivors reported use for medical purposes (82.23% vs. 62.58%). After adjusting for state-level policy, biological sex, age, educational attainment, self-reported race/ethnicity, home ownership, mental health status and physical health status, current smoking (odds ratio [OR], 5.14 vs. 3.74) and binge drinking (OR, 2.71 vs. 2.69) were associated with cannabis use in both groups. Characteristics associated with medical cannabis use varied for the two groups; however, daily use (20-30 days; OR, 1.72 vs. 2.43) was associated with cannabis use for medical purposes in both groups after adjusting for other variables in the model.
Conclusions: A high proportion of individuals report cannabis use for medical purposes with higher rates among cancer survivors. Findings support the urgent need for ongoing cannabis research to better understand and inform its use for medical purposes, as well as the development of high-quality standardized education materials and clinical practice guidelines.
Keywords: Behavioral Risk Factor Surveillance System; cancer survivor; cannabis; medical marijuana; smoking.
© 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Similar articles
-
Core state preconception health indicators – pregnancy risk assessment monitoring system and behavioral risk factor surveillance system, 2009.MMWR Surveill Summ. 2014 Apr 25;63(3):1-62.PMID: 24759729
-
Sociodemographic Characteristics Associated With and Prevalence and Frequency of Cannabis Use Among Adults in the US.JAMA Netw Open. 2021 Nov 1;4(11):e2136571. doi: 10.1001/jamanetworkopen.2021.36571.PMID: 34846523 Free PMC article.
-
Self-Reported Medical and Nonmedical Cannabis Use: Results from the 2018 Behavioral Risk Factor Surveillance System in 14 States.J Community Health. 2022 Aug;47(4):641-649. doi: 10.1007/s10900-021-01049-1. Epub 2022 Apr 23.PMID: 35460471 Free PMC article.
-
Qualitative Research Informing a Preference Study on Selecting Cannabis for Cancer Survivor Symptom Management: Design of a Discrete Choice Experiment.Patient. 2022 Jul;15(4):497-507. doi: 10.1007/s40271-021-00567-3. Epub 2022 Feb 8.PMID: 35132605 Free PMC article. Review.
-
Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations.Am J Public Health. 2017 Aug;107(8):e1-e12. doi: 10.2105/AJPH.2017.303818. Epub 2017 Jun 23.PMID: 28644037 Free PMC article. Review.
References
REFERENCES
-
- Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA A Cancer J Clin. 2019;69(5):363-385. doi:10.3322/caac.21565
-
- Mitchell AJ, Ferguson DW, Gill J, Paul J, Symonds P. Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis. Lancet Oncol. 2013;14(8):721-732. doi:10.1016/s1470-2045(13)70244-4
-
- Shi Q, Smith TG, Michonski JD, Stein KD, Kaw C, Cleeland CS. Symptom burden in cancer survivors 1 year after diagnosis: a report from the American Cancer Society’s Studies of Cancer Survivors. Cancer. 2011;117(12):2779-2790. doi:10.1002/cncr.26146
-
- Dulaney C, Wallace AS, Everett AS, Dover L, McDonald A, Kropp L. Defining health across the cancer continuum. Cureus. 2017;9(2). doi:10.7759/cureus.1029
-
- Strasser F, Luftner D, Possinger K, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol. 2006;24(21):3394-3400. doi:10.1200/jco.2005.05.1847